Clinical Trials on ERAS in China
Total 38 results
-
Shanghai Zhongshan HospitalRecruiting
-
Weibing TangCompleted
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitation
-
Chinese PLA General HospitalZhejiang UniversityRecruitingSolid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12CChina
-
The Second Hospital of Shandong UniversityRecruitingLung Cancer | Surgery | ERASChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
The Second Hospital of Shandong UniversityRecruitingLung Diseases | Surgery | ERASChina
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedKnee Osteoarthritis | ERASChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingKRAS G12C Mutant Advanced Solid TumorsChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingSolid Tumor | KRAS Mutation-Related TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
BeBetter Med IncXiangya Hospital of Central South UniversityRecruitingAdvanced or Metastatic Solid Tumor | KRAS G12C MutationChina
-
Boehringer IngelheimCompletedSolid Tumors, KRAS MutationJapan
-
Peking University Cancer Hospital & InstituteRecruiting
-
D3 Bio (Wuxi) Co., LtdRecruitingKRAS P.G12CAustralia, Korea, Republic of, China, United States, Hong Kong
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimRecruitingSolid Tumor, KRAS MutationUnited States, Taiwan, Japan
-
AmgenActive, not recruitingKRAS p.G12C Mutant Advanced Solid TumorsUnited States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
-
Beijing HospitalBethune Charitable FoundationRecruitingICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCMetastatic Colorectal Cancer | MSS | RAS MutationChina
-
Chinese PLA General HospitalRecruitingColorectal Neoplasms | Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS MutationChina
-
Tianshu LiuUnknownIncurable Colorectal Cancer | RAS-wild-typeChina
-
Zhejiang UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedDigestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-typeChina
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingMetastatic Colorectal Cancer | Microsatellite Stable | RAS MutationChina
-
Fudan UniversityRecruitingMetastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | CadonilimabChina
-
Hunan Province Tumor HospitalEnrolling by invitationKRAS Gene Mutation Advanced Non-small Cell Lung CancerChina
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutatedChina
-
Second Affiliated Hospital, School of Medicine,...Changxing People's HospitalRecruitingUnresectable Colon Cancer Peritoneal Metastases | PMMR/Ras/BRAF Wild-typeChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingPancreatic Cancer | KRAS P.G12CChina
-
AmgenRecruitingAdvanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
-
Haihe Biopharma Co., Ltd.TerminatedMelanoma | Erdheim-Chester Disease | Non-Small-Cell Lung Cancer | Advanced Tumors | Other RAS/RAF/MEK/ERK Mutated TumorsUnited States, China
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingColorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12CChina
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, ColorectalUnited States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
National Cancer Institute (NCI)Active, not recruitingKRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7United States